Diabetes

November 14, 2019
Published by admin_auro at November 14, 2019
Categories

Curing, preventing and reversing diabetes with a commonly available blood pressure drug Hydralazine: Hydralazine-based therapy for TIIDM and obesity-associated metabolic deficits: Hydralazine (trade name: Apresoline, BiDil, and others), a vasodilator used in the treatment of high blood pressure,  cardiac failure and others, increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, decreases TXNIP expression, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM, via down-regulation of its target gene, 14/November/2019, 9.58 am

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that “MC4R-dependent […]
Do you like it?0
Read more
September 4, 2019
Published by admin_auro at September 4, 2019
Categories

New Mechanistic and functional  insights into how Teneligliptin mitigates complications of diabetes and obesity:  Teneligliptin (brand names: Tenelin), a DPP4 (dipeptidyl peptidase 4 ) inhibitor,  augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates diabetes mellitus, via down regulation of its target gene, 4/September/2019, 9.30 am

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection […]
Do you like it?0
Read more
August 25, 2019
Published by admin_auro at August 25, 2019
Categories

New Mechanistic and functional insights into how Vildagliptin mitigates complications of diabetes and obesity:  Vildagliptin/LAF237 (brand names: Galvus/Vildagluse/Gliptus), a DPP4 (dipeptidyl peptidase 4 ) inhibitor,  augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates diabetes mellitus, via down regulation of its target gene, 25/August/2019, 11.49 pm

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection […]
Do you like it?0
Read more
August 23, 2019
Published by admin_auro at August 23, 2019
Categories

The Mechanistic basis of how Liraglutide mitigates complications of diabetes and obesity:  Liraglutide (trade name: Victoza, Saxenda), a Glucagon-like peptide-1  (GLP-1) receptor agonist,  augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates diabetes mellitus, via down regulation of its target gene, 24/August/2019, 12.27 am

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection […]
Do you like it?0
Read more
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112
Next page